Monopar Therapeutics
MNPRFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Monopar Therapeutics Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Jun 30, 2024; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 2024-06-30 | 7,922 | $5.78K | SEC filing |
| Rappaport Reiches Capital Management, LLC | 2024-06-30 | 10,695 | $7.81K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2024-06-30 | 561 | $410 | SEC filing |
| TWO SIGMA SECURITIES, LLC | 2024-06-30 | 47,058 | $34.4K | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2024-06-30 | 194,298 | $145K | SEC filing |
| Virtu Financial LLC | 2024-06-30 | 18,840 | Not shown | SEC filing |
| NewEdge Advisors, LLC | 2024-06-30 | 3,000 | $2.19K | SEC filing |
| VANGUARD GROUP INC | 2024-06-30 | 45,167 | $33K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2024-06-30 | 60,036 | $44.9K | SEC filing |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 2024-06-30 | 0 | $0 | SEC filing |
| WELLS FARGO & COMPANY/MN | 2024-06-30 | 2,500 | $1.83K | SEC filing |
| GERBER, LLC | 2024-06-30 | 28,005 | $20.4K | SEC filing |
| Federation des caisses Desjardins du Quebec | 2024-06-30 | 80 | $58 | SEC filing |
| MORGAN STANLEY | 2024-03-31 | 800 | $545 | SEC filing |
| MORGAN STANLEY | 2024-03-31 | 800 | $545 | SEC filing |
| MORGAN STANLEY | 2023-12-31 | 800 | Not shown | SEC filing |
| Federation des caisses Desjardins du Quebec | 2023-12-31 | 80 | Not shown | SEC filing |
| Federation des caisses Desjardins du Quebec | 2023-09-30 | 80 | Not shown | SEC filing |
- Each value is checked against Monopar Therapeutics's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Monopar Therapeutics's share price.
- Value not shown for 3 rows: no share price from within three months of their report dates is on file, so they could not be checked.
- 1 row left out: the value per share it reports is far from Monopar Therapeutics's share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so it may describe another security or share class.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Federation des caisses Desjardins du Quebec: 80 shares reported 2023-12-31; 80 shares reported 2024-06-30.
- Federation des caisses Desjardins du Quebec: 80 shares reported 2023-09-30; 80 shares reported 2023-12-31.
13 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Monopar Therapeutics's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-06-20 · Cittadine Andrew: Larger than all 13 other insider purchases of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-26 | Vu Quan Anh · Chief Financial Officer | Common Stock | P — Open market or private purchase | +1,500 | 69.95 | SEC filing |
| 2025-12-18 | KLAUSNER ARTHUR J · Director | Common Stock | S — Open market or private sale | −461 | 68.09 | SEC filing |
| 2025-12-18 | KLAUSNER ARTHUR J · Director | Common Stock | S — Open market or private sale | −4,660 | 67.06 | SEC filing |
| 2025-09-24 | Tactic Pharma LLC · Chief Executive Officer | Common Stock | S — Open market or private sale | −550,229 | 63.61 | SEC filing |
| 2025-07-14 | Robinson Chandler · Chief Executive Officer | Common Stock | S — Open market or private sale | −16,800 | 40.00 | SEC filing |
| 2025-07-14 | STARR CHRISTOPHER M · Director | Common Stock | S — Open market or private sale | −16,800 | 40.00 | SEC filing |
| 2025-07-14 | Tsuchimoto Kim R · Director | Common Stock | S — Open market or private sale | −8,904 | 40.00 | SEC filing |
| 2025-04-02 | Tactic Pharma LLC · Chief Executive Officer | Common Stock | S — Open market or private sale | −33,334 | 35.00 | SEC filing |
Showing 8 of 17 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-26 | Sweeny Nicole · Director | Stock Options | A — Grant, award, or other acquisition | +1,284 | SEC filing |
| 2026-03-31 | Robinson Chandler · Chief Executive Officer | Restricted Stock Unit | M — Exercise or conversion of derivative security | −6,732 | SEC filing |
| 2026-03-31 | Cittadine Andrew · Chief Operating Officer | Restricted Stock Unit | M — Exercise or conversion of derivative security | −3,514 | SEC filing |
| 2026-03-31 | Robinson Chandler · Chief Executive Officer | Common Stock | M — Exercise or conversion of derivative security | +6,732 | SEC filing |
| 2026-03-31 | Cittadine Andrew · Chief Operating Officer | Common Stock | M — Exercise or conversion of derivative security | +3,514 | SEC filing |
| 2026-03-31 | Robinson Chandler · Chief Executive Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −1,972 | SEC filing |
| 2026-03-31 | Cittadine Andrew · Chief Operating Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −1,571 | SEC filing |
| 2026-03-02 | Rodriguez Susan · CCSO | Stock Options | A — Grant, award, or other acquisition | +48,728 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-12-16 | Hendricks Diane · 10% owner | Common Stock | J — Other acquisition or disposition | −43,499 | SEC filing |
| 2025-12-16 | KLAUSNER ARTHUR J · Director | Common Stock | J — Other acquisition or disposition | +7,710 | SEC filing |
| 2025-01-28 | Robinson Chandler · Chief Executive Officer | Common Stock | J — Other acquisition or disposition | +62,815 | SEC filing |
| 2024-12-09 | TacticGem LLC · 10% owner | Common Stock | J — Other acquisition or disposition | −1,433,334 | SEC filing |
Showing 4 of 4 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.